By Counterforce Health Team in Fabrazyme (agalsidase beta) —

How to Get Fabrazyme (agalsidase beta) Covered by Cigna in New York: Prior Authorization, Appeals, and State Review Options

Answer Box: Getting Fabrazyme Covered by Cigna in New York

Cigna typically covers Fabrazyme (agalsidase beta) for confirmed Fabry disease as a specialty medication requiring prior authorization. Fastest path to approval: Have your specialist (geneticist, metabolic endocrinologist, or nephrologist) submit a complete PA request through Cigna's provider portal with genetic testing results and clinical documentation. If denied, New York residents can appeal through Cigna's internal process (180-day deadline), then request external review through the New York Department of Financial Services within 4 months. Start today: Verify your plan covers specialty medications through Accredo and ask your prescriber to begin the PA submission.

Table of Contents

  1. What This Guide Covers
  2. Before You Start: Verify Your Coverage
  3. Gather What You Need
  4. Submit the Prior Authorization Request
  5. Follow-Up and Timeline Management
  6. If You're Asked for More Information
  7. If Your Request is Denied
  8. New York External Review Process
  9. Renewal and Re-authorization
  10. Quick Reference Checklist

What This Guide Covers

This guide helps New York patients and their healthcare teams navigate Cigna's prior authorization process for Fabrazyme (agalsidase beta), an enzyme replacement therapy for Fabry disease. We'll walk you through the requirements, timelines, and appeal options specific to New York state law.

Fabrazyme typically costs around $7,600 per 35-mg vial, making insurance coverage essential for most patients. While Cigna generally covers specialty medications like Fabrazyme, prior authorization is almost always required, and the process can take several weeks without proper preparation.

Before You Start: Verify Your Coverage

Check Your Plan Type and Formulary

First, confirm that your Cigna plan includes specialty drug coverage. Most Cigna plans use Accredo as the designated specialty pharmacy for high-cost medications like Fabrazyme.

Log into your myCigna member portal to:

  • Verify Fabrazyme appears on your plan's formulary
  • Check if it's listed as "PA" (prior authorization required)
  • Confirm whether it's covered under pharmacy or medical benefits
Note: Fabrazyme is typically placed on Tier 4 or 5 (specialty tier) with higher cost-sharing, but coverage depends on your specific plan design.

Confirm Network Status

Ensure your prescribing specialist is in-network with Cigna. Most plans require that Fabrazyme be prescribed by or in consultation with:

  • Medical geneticist
  • Metabolic endocrinologist
  • Nephrologist with Fabry disease expertise
  • Cardiologist specializing in lysosomal storage disorders

Gather What You Need

Required Documentation

Diagnosis and Testing:

Clinical Evidence:

  • ICD-10 diagnosis code (E75.21 for Fabry disease)
  • Documentation of Fabry-related symptoms or organ involvement
  • Prior treatment history and outcomes
  • Current clinical status and treatment goals

Prescriber Information:

  • Specialist credentials and qualifications
  • Treatment plan with dosing rationale (1 mg/kg every 2 weeks)
  • Site of care plan (infusion center or home infusion)
From our advocates: "We've seen the strongest approvals when genetic testing clearly shows a pathogenic variant and the clinical summary connects specific symptoms to Fabry disease progression. Don't assume the reviewer knows how enzyme deficiency causes the patient's kidney or heart problems—spell it out clearly."

Submit the Prior Authorization Request

Step-by-Step Submission Process

1. Obtain the Correct PA Form Contact Cigna provider services at the number on your insurance card to request the current Fabrazyme prior authorization form. Many plans use a "Fabry's Disease Standard Request" form.

2. Complete the Clinical Section Your specialist should include:

  • Confirmed Fabry disease diagnosis with supporting lab results
  • Clinical rationale for enzyme replacement therapy
  • Dosing calculation based on patient weight
  • Expected treatment outcomes and monitoring plan

3. Submit Through Preferred Channel Most providers submit through:

4. Include All Supporting Documents

  • Complete genetic testing report
  • Enzyme activity results
  • Recent clinical notes
  • Any relevant imaging or lab work

Follow-Up and Timeline Management

Standard Processing Times

What to Track

Keep a log with:

  • Submission date and reference number
  • Follow-up call dates and contact names
  • Any additional information requests
  • Decision date and outcome
Tip: Call Cigna every 7-10 business days for status updates. Ask for the case reference number and document who you spoke with.

If You're Asked for More Information

Cigna may request additional clinical documentation, particularly:

  • More detailed genetic testing interpretation
  • Evidence of disease progression or symptom severity
  • Justification for enzyme replacement over oral chaperone therapy (migalastat)
  • Specialist consultation notes

Respond quickly to these requests—delays can restart the review clock. Counterforce Health can help organize clinical evidence and craft targeted responses to specific medical necessity questions.

If Your Request is Denied

Common Denial Reasons and Solutions

Denial Reason How to Address
Insufficient genetic confirmation Submit complete molecular genetic testing report with pathogenic variant classification
Non-specialist prescriber Obtain consultation letter from qualified geneticist or metabolic specialist
Lack of clinical evidence Provide detailed symptom documentation, organ involvement studies, biomarker levels
Step therapy requirement Request exception based on contraindications to oral therapy or urgent clinical need

Internal Appeal Process

You have up to 180 days from the denial date to file an internal appeal with Cigna. Submit:

  • Written appeal letter explaining medical necessity
  • Updated clinical documentation
  • Peer-reviewed literature supporting Fabrazyme use
  • Specialist letter addressing specific denial reasons

Cigna typically responds to internal appeals within 30 days for standard cases or 72 hours for expedited reviews.

New York External Review Process

If Cigna upholds the denial after internal appeal, New York residents can request external review through the New York Department of Financial Services (DFS).

Filing Requirements

  • Deadline: 4 months from final internal denial
  • Fee: Up to $25 (waived for financial hardship or Medicaid)
  • Timeline: 30 days for standard review, 72 hours for expedited

What DFS Reviews

The external reviewer will examine:

  • Whether the denial was appropriate under your plan terms
  • Medical necessity based on current clinical evidence
  • Compliance with New York insurance laws

New York's external appeal decisions are binding on Cigna, and the state maintains a searchable database of past decisions that can help inform your case strategy.

Getting Help with Appeals

Community Health Advocates (CHA) offers free assistance to New York residents filing insurance appeals. Call their helpline at 888-614-5400 for guidance on preparing your external review application.

Renewal and Re-authorization

Most Fabrazyme approvals are time-limited (typically 6-12 months). Start the renewal process 60-90 days before expiration.

Renewal Documentation

Include:

  • Updated clinical assessment showing treatment response
  • Current lab values (kidney function, cardiac parameters)
  • Gb3/lyso-Gb3 levels if monitored
  • Continued specialist oversight documentation
  • Any adverse events or dose adjustments

Demonstrating clinical stability or improvement strengthens renewal requests. Counterforce Health can help track key metrics and present renewal evidence effectively.

Quick Reference Checklist

Before Starting:

  • Verify Cigna specialty pharmacy coverage through Accredo
  • Confirm Fabrazyme formulary status and tier
  • Ensure specialist prescriber is in-network

Required Documents:

  • Genetic testing report showing pathogenic GLA variant
  • α-galactosidase A enzyme activity results
  • Clinical documentation of Fabry disease symptoms
  • Specialist consultation notes and treatment plan

Submission:

  • Complete PA form with all clinical sections
  • Submit through preferred electronic portal
  • Keep reference numbers and submission dates

If Denied:

  • File internal appeal within 180 days
  • Consider peer-to-peer review request
  • Prepare for DFS external review if needed

Timeline Tracking:

  • Initial decision: ~15 business days
  • Internal appeal: ~30 days
  • External review: ~30 days (4-month filing deadline)

Frequently Asked Questions

Q: How long does Cigna prior authorization take for Fabrazyme in New York? A: Standard processing is typically 15 business days, with expedited review available in 72 hours for urgent medical situations.

Q: What if Fabrazyme isn't on my Cigna formulary? A: You can request a formulary exception with clinical justification. Non-formulary drugs often require additional documentation but can still be covered.

Q: Can I request an expedited appeal in New York? A: Yes, both Cigna internal appeals and DFS external reviews offer expedited processing (72 hours) when delay could seriously jeopardize your health.

Q: Does step therapy apply if I need Fabrazyme immediately? A: You can request a step therapy exception if oral alternatives are contraindicated or clinically inappropriate for your specific case.

Q: What happens if I move to New York from another state? A: Your Cigna coverage should transfer, but you may need to establish care with New York in-network specialists and update your prior authorization.

Disclaimer: This guide provides general information about insurance processes and should not be considered medical or legal advice. Coverage decisions depend on your specific plan terms and clinical circumstances. Always consult with your healthcare provider and review your plan documents for definitive guidance.

For personalized assistance with prior authorizations and appeals, Counterforce Health helps patients and providers navigate complex coverage decisions by turning insurance denials into targeted, evidence-backed appeals.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.